Article info

Download PDFPDF

Original article
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study

Authors

  1. Correspondence to Dr Tania Mara Welzel, JW Goethe University Hospital, Department of Medicine 1, Theodor-Stern-Kai 7, Frankfurt am Main 60596, Germany; tania.welzel{at}kgu.de
View Full Text

Citation

Welzel TM, Nelson DR, Morelli G for the HCV-TARGET Study Group, et al
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study

Publication history

  • Received February 6, 2016
  • Revised June 1, 2016
  • Accepted June 4, 2016
  • First published July 13, 2016.
Online issue publication 
September 06, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.